Injection Lipolysis is a popular cosmetic medical procedure involving the subcutaneous injection into areas of adipose tissue of an intravenous preparation of phosphatidylcholine (PC) manufactured under the trade name of Lipostabil N® by Aventis.
Originally used “Off Label” in 1988 by Sergio Maggiori in the treatment of Xanthelasma, it was further developed in the use of fat cell lysis amid controversy and popularised by Dr Patricia Rittes in Brazil in the treatment of bulging lower eyelids. The lack of regulation, and popular use of PC by the Public, without medical supervision, led to a ban on the drug in Brazil.
In Europe and the United States the controlled use of PC by clinicians has been pioneered by Dr Franz Hasengschwandtner, who has been instrumental in setting up the NETWORK-Lipolysis Group in 2003.
The mode of action of PC is poorly understood has not been published in detail. It is believed to act by the lysis of the plasma membrane of adipocytes, with fat clearance via the liver, in bile, and possibly the urine.
This is an uncommissioned independent publication, representing the views of the author. The NETWORK-Lipolysis Group has cooperated with the author in the production of this volume, but has had no editorial input with respect to presentation of the available science.
Evidence, available in the public domain, is presented and critically analysed. Reviews of relevant biochemistry, membrane physiology and mechanisms of apoptosis, explain the lipolysis process. It seems likely that the initiation of lysis is a function of asymmetrical phospholipid dynamics with plasma membrane pore formation and the induction of a rapid apoptotic Caspase cascade system via TNF supragene death receptors, mitochondrial pore formation and the resulting formation of apoptosome - the final trigger. The work presented is a compilation of the scientific evidence currently available, and it is hoped that this information will assist in some clarification of lipolysis which not only involves the process of cell lysis, but also of cell clearance and soft tissue re-modelling.
The author accepts the scientific and clinical controversies and concerns surrounding the regulation of this new treatment, and also the need for formal scientific investigation of phosphatidylcholine in this area, with respect to mode of action safety issues, patient selection and outcomes. Extrapolation of published scientific evidence into the clinical situation reflects the opinions of the author (NSP) and is not necessarily the opinion or position of either the NETWORK-Lipolysis Group.
This publication should be regarded as a snapshot of current informed opinion and is an attempt to provide a balanced viewpoint on the current state of knowledge, at the time of publication. It is the essential and only published text for those engaged in the practice of Injection Lipolysis.
It is hoped that this publication will catalyse the creation of mechanisms for the appropriate assessment and regulation of drugs related to practice of cosmetic medicine, and stimulate further debate and the funding of appropriate scientific and clinical studies to confirm the mode of action, clinical safety and outcome of the use of phosphatidylcholine and injection lipolysis.
Would you like order this book?
Evidenced Based Practice:
Please click the cover.
This publication is an independent review of applied phospholipid biochemistry, plasma membranes, cell lysis and apoptosis.
Type:
Paperback - 246 x 189mm - 160 pages colour
Price:
165.00 US$ + shipping costs
Keine Kommentare:
Kommentar veröffentlichen